The ATHENA human papillomavirus study: design, methods, and baseline results.
about
Anal cancer and intraepithelial neoplasia screening: A reviewCervical Cancer Screening after Perimenopause: How Is Human Papillomavirus Test Performed?Knowledge of Patients' Human Papillomavirus Status at the Time of Cytologic Review Significantly Affects the Performance of Cervical Cytology in the ATHENA Study.Point-Counterpoint: Cervical Cancer Screening Should Be Done by Primary Human Papillomavirus Testing with Genotyping and Reflex Cytology for Women over the Age of 25 Years.Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological dataA cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese womenIs 58% sensitivity for detection of cervical intraepithelial neoplasia 3 and invasive cervical cancer optimal for cervical screening?Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.The effectiveness of targeting never or rarely screened women in a national cervical cancer screening program for underserved women.Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile.The correlation between human papillomavirus positivity and abnormal cervical cytology result differs by age among perimenopausal women.Can clinical tests help monitor human papillomavirus vaccine impact?Identifying a "range of reasonable options" for cervical cancer screening.A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United StatesHuman papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical managementEvidence and impact of human papillomavirus latency.Comparing the performance of six human papillomavirus tests in a screening populationHuman Papillomavirus Laboratory Testing: the Changing ParadigmPractice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition.Development and characterization of the cobas human papillomavirus test.HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease.Impact of Widespread Cervical Cancer Screening: Number of Cancers Prevented and Changes in Race-specific Incidence.Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, ChinaCost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screeningEvaluating HPV-negative CIN2+ in the ATHENA trial.Human papillomavirus genotypes associated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China.Testing and genotyping of high-risk human papillomavirus by the cobas HPV Test and the Hybrid Capture 2 high-risk HPV DNA test using cervical and vaginal samplesThe road ahead for cervical cancer prevention and control.Nucleic acid-based assays for the detection of high-risk human papillomavirus: a technical review.Primary human papillomavirus screening for cervical cancer in the United States-US Food and Drug Administration approval, clinical trials, and where we are today.High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis.Comparison of cobas human papillomavirus test results from primary versus secondary vials of PreservCyt specimens and evaluation of potential cross-contamination.Molecular diagnosis of infectious diseases using cytological specimens.Bethesda 2014: improving on a paradigm shift.A Model Approach for Assessing the Benefits of HPV Testing against Cytology in Screening for Cervical Cancer Precursors in Thailand
P2860
Q26769069-05654D3B-1477-42AE-90DB-275D0B1D009FQ28069711-36D7E38B-AC7B-4F3A-BE7E-D454388E0585Q30276085-2F954A9E-1D00-4AE0-AFCF-77B80D358066Q30299986-C52497D8-95C2-44E3-AB92-4FA3A127F8F4Q30829696-67B4F81E-DDED-446B-816A-767D205BC05AQ31121182-FFE12213-6A40-4BCD-8F21-7B2CB32375FAQ33679663-1F457A5A-B9B6-420E-ADA0-071B087A7A6FQ33760459-65A650F0-2B1B-4756-8CA0-795A824411A2Q34637954-9E568865-49B2-4B0E-BE30-78CAB0BA2D13Q35203306-E05CC6F5-6E2C-4E24-914A-748B03A24DB1Q35282164-8B3DD954-31AC-4D57-8260-0AEF08617647Q35809257-7664F6E6-918A-4B3C-B9CC-0D2FEC142CE8Q35870574-35ECC45D-B821-4B3B-B997-0D70A154B5D9Q36307824-B62E89A9-63AC-4B1F-995C-2E1F8EBC10B3Q36403669-275FD834-8A81-4DD7-AC96-40067875D916Q36407727-C485B361-B9B7-4276-A1CF-48450D417217Q36483052-2C422C6F-037D-4F88-9856-566BFEC3D176Q36495566-54265E01-441C-4D85-B9DC-203B8E410A3FQ36533952-03133A6B-256C-4EA9-8243-A743A07F3BC3Q36540628-FEDCEDB6-3213-4A0C-A085-DBC0FEF9F1E4Q36663594-3CBDA713-C5A9-425C-9B21-A18A6814170CQ36675236-AD00B077-AC6F-4FB8-BA75-69AB47CD8159Q36817519-36214623-3D9E-4CDD-A4D9-C9889115FE91Q36826712-D45F635C-E020-4730-A634-7C93CF6F9A29Q36856284-964DEF90-367E-47AC-AFF4-27401FE87B50Q37119762-312788E7-CE67-46D5-8F08-DA8AB14208AEQ37177735-13D3538D-3140-4949-B184-4A174F9EA77DQ37204991-15AA0E47-53C5-466D-AD04-A44E86F48DCDQ37273434-D500B051-4059-4B13-A38E-3416CEB85ABAQ37349000-FC4B7BF1-B7CB-45AD-A1A5-15DBD3F6757BQ37604761-B6C1AEBB-B515-4823-B30D-DAA9199AA879Q37713689-6AAB1453-1070-49E8-BF2F-9CFE95B6F664Q37719631-3B582853-F88A-4867-A0AD-A0F047196056Q38221059-422DBD9C-BC7F-4282-84C3-A5F0A957D2E5Q38250275-13E07837-686E-47BC-B67D-082DC26F6BF9Q38316273-364DE816-794A-4DCC-BCBB-0A818347E7EEQ38402711-5CDF4486-7DF5-4CF6-BD8D-E0DB5852471BQ38653739-8C94C4D1-1842-4989-A22A-5210376D3C28Q38696662-2CD8B5B2-7515-4381-9D44-70C8BF5BA42AQ38727352-00E9D8E4-D29B-4075-B292-23F848EFEE73
P2860
The ATHENA human papillomavirus study: design, methods, and baseline results.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The ATHENA human papillomavirus study: design, methods, and baseline results.
@en
The ATHENA human papillomavirus study: design, methods, and baseline results.
@nl
type
label
The ATHENA human papillomavirus study: design, methods, and baseline results.
@en
The ATHENA human papillomavirus study: design, methods, and baseline results.
@nl
prefLabel
The ATHENA human papillomavirus study: design, methods, and baseline results.
@en
The ATHENA human papillomavirus study: design, methods, and baseline results.
@nl
P2093
P1476
The ATHENA human papillomavirus study: design, methods, and baseline results.
@en
P2093
Catherine M Behrens
Mark H Stoler
Raymond Apple
Teresa L Wright
Thomas C Wright
Toniann Derion
P304
46.e1-46.e11
P356
10.1016/J.AJOG.2011.07.024
P407
P577
2011-07-22T00:00:00Z